Today's Low
₹ 128.45
Today's High
₹ 133.00
52 Weeks Low
₹ 98.45
52 Weeks High
₹ 164.40
Lower
₹ 103.05
Upper
₹ 154.55
Lyka Labs Limited engages in the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. It manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. The company also provides contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, BA/BE clinical study data, etc. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. Lyka Labs Limited offers its products in various formulations, including injections, creams, ointments, foams, gels, and lotions. Further, the company exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 44.2 | 52.2 | 29.1 | 35.9 | 35.1 | 49.1 | 62.8 | 81.8 | 101.7 | 118.1 | 126.7 | 115.0 |
Total Non-Current Assets | 107.3 | 133.4 | 144.6 | 152.0 | 167.8 | 176.2 | 186.1 | 158.7 | 177.1 | 211.2 | 162.2 | 167.5 |
Total Assets | 151.5 | 185.6 | 173.7 | 187.9 | 202.9 | 225.2 | 248.9 | 240.5 | 278.8 | 329.3 | 288.9 | 282.5 |
Total Current Liabilities | 32.6 | 99.4 | 49.9 | 66.3 | 84.8 | 167.1 | 165.5 | 162.8 | 195.2 | 208.1 | 147.2 | 132.5 |
Total Non-Current Liabilities | 73.3 | 72.8 | 148.9 | 136.7 | 72.3 | 5.3 | 38.7 | 28.5 | 37.0 | 65.2 | 71.9 | 74.5 |
Shareholder's Funds | 45.4 | 13.3 | -25.8 | -14.3 | 43.0 | 49.5 | 37.7 | 45.2 | 43.1 | 52.7 | 67.0 | 73.9 |
Total Liabilities | 151.5 | 185.6 | 173.7 | 187.9 | 202.9 | 225.2 | 248.9 | 240.5 | 278.8 | 329.3 | 288.9 | 282.5 |
The Industry Price to BV stands at 6.03, vs the Price to BV of 6.08, which results in a Positive aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of -9.85, which results in a Positive aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 0.54, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.44, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 93.1 | 194.1 | 86.3 | 61.5 | 70.8 | 59.8 | 110.1 | 130.4 | 166.3 | 118.9 | 127.1 | 169.9 |
Total Expenditure | 76.2 | 92.9 | 66.6 | 65.2 | 72.7 | 63.4 | 87.3 | 110.3 | 137.6 | 110.3 | 105.6 | 154.9 |
Operating Profit(Excl OI) | 20.2 | 103.2 | 21.3 | -0.6 | 0.2 | -1.4 | 25.0 | 22.2 | 31.0 | 13.9 | 24.9 | 19.1 |
Add: Other Income | 3.4 | 2.1 | 1.6 | 3.1 | 2.1 | 2.1 | 2.2 | 2.1 | 2.4 | 5.4 | 3.4 | 4.1 |
Operating Profit | 20.2 | 103.2 | 21.3 | -0.6 | 0.2 | -1.4 | 25.0 | 22.2 | 31.0 | 13.9 | 24.9 | 19.1 |
Less: Interest | 11.9 | 20.1 | 25.9 | 20.1 | 7.2 | 9.6 | 18.7 | 16.4 | 25.6 | 28.5 | 20.8 | 30.4 |
PBDT | 8.4 | 83.1 | -4.7 | -20.7 | -7.0 | -11.0 | 6.3 | 5.8 | 5.4 | -14.6 | 4.1 | -11.2 |
Less: Depreciation Amortization | 14.2 | 17.4 | 8.3 | 8.0 | 7.3 | 11.3 | 10.3 | 9.3 | 10.9 | 8.8 | 11.7 | 8.7 |
PBT & Exceptional Items | -5.8 | 65.8 | -13.0 | -28.7 | -14.3 | -22.3 | -4.0 | -3.5 | -5.4 | -23.4 | -7.6 | -19.9 |
Less: Exceptional Income Expenses | -7.4 | -6.5 | -1.1 | -33.2 | -1.1 | 2.2 | -4.1 | 7.4 | 1.8 | 19.4 | 8.0 | 12.3 |
Profit Before Tax | -13.2 | 59.3 | -14.1 | -61.9 | -15.4 | -20.0 | -8.1 | 3.9 | -3.7 | -4.1 | 0.4 | -7.5 |
Less: Taxation | 0.0 | 20.8 | -4.1 | 0.7 | -9.1 | -1.0 | -1.5 | -0.2 | 1.1 | 1.3 | 0.0 | 0.0 |
Profit After Tax | -13.2 | 38.4 | -10.1 | -62.6 | -6.4 | -19.0 | -6.6 | 4.1 | -4.7 | -5.3 | 0.4 | -7.5 |
Earnings Per Share | 0.0 | 0.1 | 0.0 | -0.2 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 0.00, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Growth stands at 32.18, vs the PAT Growth of -885.87, which results in a Negative aspect.
The Industry PAT Margin stands at 9.77, vs the PAT Margin of -101.84, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -13.2 | 59.2 | -14.1 | -61.9 | -15.4 | -20.0 | -8.1 | 3.7 | -4.9 | -6.6 | -0.7 | -6.9 |
Tax Paid | 0.2 | -0.9 | -0.8 | 0.5 | -1.1 | -0.4 | -1.2 | -0.3 | -0.1 | 1.0 | -0.4 | 0.6 |
Adjustment | 31.8 | 41.9 | 35.4 | 55.8 | 15.2 | 20.8 | 30.5 | 16.2 | 31.6 | 32.9 | 17.4 | 24.1 |
Changes In Working Capital | -13.2 | 59.2 | -14.1 | -61.9 | -15.4 | -20.0 | -8.1 | 3.7 | -4.9 | -6.6 | -0.7 | -6.9 |
Cash Flow after changes in Working Capital | 8.7 | 80.2 | 9.6 | 4.8 | 27.4 | 11.1 | 32.5 | 12.3 | 25.9 | 93.2 | 11.2 | 0.9 |
Cash Flow from Operating Activities | 9.0 | 79.2 | 8.8 | 5.3 | 26.7 | 10.9 | 31.4 | 11.9 | 26.5 | 89.1 | 10.9 | 1.2 |
Cash Flow from Investing Activities | 7.4 | -6.2 | -0.2 | -0.1 | -4.0 | -3.2 | -12.7 | 17.3 | 29.0 | -56.9 | 4.5 | 11.9 |
Cash Flow from Financing Activities | -21.6 | -63.2 | -11.8 | 3.4 | -23.4 | -10.4 | -19.1 | -30.2 | -59.7 | -26.3 | -12.5 | -16.3 |
Net Cash Inflow / Outflow | -5.3 | 9.9 | -3.1 | 8.6 | -0.7 | -2.7 | -0.4 | -1.0 | -4.2 | 5.9 | 3.0 | -3.3 |
Opening Cash & Cash Equivalents | 17.1 | 7.2 | 10.3 | 1.7 | 2.4 | 5.1 | 5.6 | 6.5 | 10.7 | 4.8 | 1.8 | 5.1 |
Closing Cash & Cash Equivalent | 11.7 | 17.1 | 7.2 | 10.3 | 1.7 | 2.4 | 5.1 | 5.6 | 6.5 | 10.7 | 4.8 | 1.8 |
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 6.87, which results in a Negative aspect.
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of -0.82, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 325.6 | 279.9 | 228.8 | 222.4 | 178.2 | 255.3 | 274.9 | 351.9 | 355.7 | 738.9 | 494.4 | 242.6 | 268.1 | 174.6 | 177.2 | 150.7 |
Total Income | 331.1 | 282.3 | 232.5 | 226.7 | 188.8 | 267.2 | 282.1 | 357.2 | 359.8 | 745.8 | 499.1 | 248.2 | 271.0 | 178.2 | 180.8 | 162.4 |
Total Expenditure | 257.0 | 238.1 | 202.3 | 189.4 | 156.0 | 205.0 | 211.9 | 225.8 | 225.5 | 282.6 | 195.4 | 180.2 | 208.0 | 140.0 | 137.5 | 147.7 |
PBIDT (Excl OI) | 68.6 | 41.8 | 26.4 | 33.0 | 22.1 | 50.3 | 63.0 | 126.0 | 130.2 | 456.3 | 299.0 | 62.4 | 60.2 | 34.6 | 39.7 | 3.0 |
Other Income | 5.4 | 2.5 | 3.8 | 4.3 | 10.7 | 11.9 | 7.2 | 5.3 | 4.1 | 6.9 | 4.7 | 5.5 | 2.9 | 3.6 | 3.6 | 11.7 |
Operating Profit | 74.1 | 44.3 | 30.2 | 37.2 | 32.8 | 62.2 | 70.2 | 131.4 | 134.3 | 463.2 | 303.7 | 68.0 | 63.0 | 38.2 | 43.3 | 14.7 |
Interest | 12.8 | 11.9 | 13.5 | 28.5 | 30.8 | 30.3 | 29.1 | 29.9 | 46.4 | 55.7 | 69.3 | 63.7 | 65.9 | 66.0 | 63.8 | 55.7 |
Exceptional Items | 0.0 | -4.4 | 0.0 | -4.1 | -70.1 | -2.1 | 2.3 | -28.0 | 1.8 | -38.9 | 0.0 | -10.5 | 4.1 | -4.8 | 0.0 | -67.4 |
PBDT | 61.3 | 28.0 | 16.7 | 4.7 | -68.2 | 29.8 | 43.5 | 73.4 | 89.6 | 368.5 | 234.4 | -6.3 | 1.3 | -32.6 | -20.6 | -108.5 |
Depreciation | 28.4 | 36.0 | 34.7 | 34.7 | 34.7 | 36.2 | 35.9 | 94.6 | 22.4 | 35.2 | 21.3 | 20.2 | 21.2 | 21.1 | 20.8 | 20.3 |
Profit Before Tax | 32.9 | -7.9 | -18.0 | -30.0 | -102.9 | -6.4 | 7.6 | -21.2 | 67.2 | 333.3 | 213.1 | -26.5 | -19.9 | -53.6 | -41.4 | -128.8 |
Tax | 12.7 | -1.8 | 1.3 | 0.0 | 2.3 | -3.0 | 0.5 | 128.8 | 4.4 | 56.6 | 18.3 | -42.2 | -1.4 | 3.6 | -0.6 | 10.6 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 20.1 | -6.2 | -19.3 | -30.0 | -105.2 | -3.4 | 7.1 | -149.9 | 62.8 | 276.8 | 194.8 | 15.7 | -18.6 | -57.2 | -40.9 | -139.4 |
Net Profit | 20.1 | -6.2 | -19.3 | -30.0 | -105.2 | -3.4 | 7.1 | -149.9 | 62.8 | 276.8 | 194.8 | 15.7 | -18.6 | -57.2 | -40.9 | -139.4 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 330.9 | 330.9 | 330.9 | 306.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 | 286.9 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 0.5 | -0.2 | -0.6 | -1.1 | -3.6 | -0.1 | 0.2 | -5.3 | 2.1 | 9.9 | 6.8 | 0.4 | -0.8 | -2.0 | -1.6 | -5.7 |
Operating Profit Margin | 22.7 | 15.8 | 13.2 | 16.7 | 18.4 | 24.4 | 25.5 | 37.3 | 37.7 | 62.7 | 61.4 | 28.0 | 23.5 | 21.9 | 24.4 | 9.7 |
Net Profit Margin | 6.2 | -2.2 | -8.4 | -13.5 | -59.1 | -1.3 | 2.6 | -42.6 | 17.6 | 37.5 | 39.4 | 6.5 | -6.9 | -32.8 | -23.1 | -92.5 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of -13.13, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -46.94, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 140.85 | 146.43 | 132.15 |
R3 | 137.57 | 137.85 | 130.50 |
R2 | 134.28 | 134.43 | 129.95 |
R1 | 131.57 | 131.85 | 129.40 |
Pivot | 128.28 | 128.43 | 128.28 |
S1 | 125.57 | 125.85 | 128.30 |
S2 | 122.28 | 122.43 | 127.75 |
S3 | 119.57 | 119.85 | 127.20 |
S4 | 116.85 | 110.43 | 125.55 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
91.78
Bearish
RSI
60.42
Neutral
ROC
15.01
Bullish
UltimateOscillator
46.87
Neutral
Williams Indicator
-17.04
Bearish
CCI Indicator
99.06
Neutral
MACD
-2,834.11
Bearish
Stochastic Indicator
81.72
Neutral
ATR
6.05
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
16-04-2024 | Inter alia, to consider and approve :- (1) to allot and issue 2600000 equity shares upon conversion of 2600000 warrants to Ipca Laboratories Limited. |
08-02-2024 | Quarterly Results |
02-11-2023 | Quarterly Results |
02-08-2023 | Quarterly Results |
23-05-2023 | Audited Results |
18-04-2023 | Inter alia: to allot and issue 24,00,000 Equity Shares upon conversion of 24,00,000 Warrants to Ipca Laboratories Limited, part of a ?Promoter Group?. |
15-03-2023 | Preferential Issue of shares & Issue Of Warrants Inter alia: to allot and issue 20,00,000 Equity Shares and 50,00,000 Warrants convertible into Equity Shares to Ipca Laboratories Limited and to approve draft of Postal Ballot Notice for seeking approval of shareholders for Re-appointment of Mr. Yogesh Shah as an Executive Director. |
07-02-2023 | Quarterly Results |
21-01-2023 | Issue Of Warrants & Preferential Issue of shares Inter alia to consider and evaluate proposal for raising of funds by way of issue of equity shares or any other eligible convertible securities, through permissible modes or combination of both, subject to all such regulatory/ statutory approvals as may be required including the approval of shareholders of the Company. |
09-11-2022 | Quarterly Results |
05-09-2022 | Inter alia, to consider and approve: 1. Sale of Land at Dharampur, Valsad and premises situated at Shivshakti Industrial Estate, Andheri East. |
08-08-2022 | Quarterly Results & Amalgamation |
20-05-2022 | Audited Results |
20-01-2022 | Quarterly Results |
29-10-2021 | Quarterly Results |
04-08-2021 | Quarterly Results |
02-06-2021 | Audited Results |